A Review of the Progress and Challenges of Developing Dendritic-Based Vaccines Against Hepatitis B Virus (Hbv) Publisher Pubmed



A Ameri ALI ; H Gandomkar HOSSEIN ; Hh Ahmed Hanan HASSAN ; Ra Kareem Radhwan ABDUL ; Hn Sameer Hayder NAJI ; A Yaseen AHMED ; Zh Athab Zainab H ; M Adil MOHANED ; I Ghasemzadeh IMAN
Source: Pathology Research and Practice Published:2025

Abstract

Hepatitis B virus (HBV) infections that last a long time are a significant public health problem worldwide. About 254 million people around the world are chronically sick with HBV. Each year, 1.2 million new cases occur, and in 2022, 1.1 million people will die from the disease. So, it has been essential to work on finding ways to treat and avoid HBV. The process of therapeutic vaccination involves giving people a non-infectious form of a virus to start or improve immune reactions specific to HBV. This helps keep HBV infections under control. Dendritic cells (DCs) play a significant part in beginning the adaptive immune response, which could decide how well an HBV infection is treated. DC-based treatment has been looked into for people with chronic HBV (CHB) infection and has shown some sound effects. Vaccines for CHB that use DCs boost antiviral immunity by improving T cells and breaking the immune system's resistance against HBV. In these vaccines, DCs are loaded with HBV antigens (like HBsAg, HBcAg, or peptides) outside of the body and then put back into the patient to make the immune system work better. In conclusion, this DC treatment is a biological therapy method with a good chance of being used. This study examined the different DC-based medicines that can treat and prevent HBV. Finally, we've talked about clinical studies, the current problems, how to fix them, and the future of this vaccine for treating and preventing HBV. This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine